Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares traded -3.47% lower at $2.50 on Wall Street last session.
In accordance with the data, 10 analysts cover Karyopharm Therapeutics Inc. (NASDAQ:KPTI). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $5.00, we find $7.50. Given the previous closing price of $2.59, this indicates a potential upside of 189.58 percent. KPTI stock price is now -27.03% away from the 50-day moving average and -38.93% away from the 200-day moving average. The market capitalization of the company currently stands at $280.40M.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
It has been rated a hold by 4 analysts and a buy by 4. Brokers who have rated the stock have averaged $7.20 as their price target over the next twelve months.
.
In other news, Paulson Richard A., President and CEO sold 3,805 shares of the company’s stock on May 04. The stock was sold for $12,753 at an average price of $3.35. Upon completion of the transaction, the President and CEO now directly owns 812,814 shares in the company, valued at $2.03 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 20, EVP & Chief Medical Officer Rangwala Reshma sold 6,770 shares of the business’s stock. A total of $27,416 was realized by selling the stock at an average price of $4.05. This leaves the insider owning 158,230 shares of the company worth $0.4 million. Insiders disposed of 658,256 shares of company stock worth roughly $1.65 million over the past 1 year. A total of 1.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in KPTI stock. A new stake in Karyopharm Therapeutics Inc. shares was purchased by SILVERARC CAPITAL MANAGEMENT, LLC during the first quarter worth $3,854,000. ALTIUM CAPITAL MANAGEMENT LP invested $1,264,000 in shares of KPTI during the first quarter. In the first quarter, IKARIAN CAPITAL, LLC acquired a new stake in Karyopharm Therapeutics Inc. valued at approximately $750,000. ALPHACENTRIC ADVISORS LLC acquired a new stake in KPTI for approximately $600,000. PROFUND ADVISORS LLC purchased a new stake in KPTI valued at around $419,000 in the second quarter. In total, there are 221 active investors with 88.20% ownership of the company’s stock.
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) opened at $2.5900 on Wednesday. During the past 12 months, Karyopharm Therapeutics Inc. has had a low of $2.28 and a high of $6.84. The fifty day moving average price for KPTI is $3.4058 and a two-hundred day moving average price translates $4.0806 for the stock.
The latest earnings results from Karyopharm Therapeutics Inc. (NASDAQ: KPTI) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.3, beating analysts’ expectations of -$0.37 by 0.07. This compares to -$0.53 EPS in the same period last year. The company reported revenue of $38.7 million for the quarter, compared to $47.67 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -18.82 percent. For the current quarter, analysts expect KPTI to generate $36.01M in revenue.
Karyopharm Therapeutics Inc.(KPTI) Company Profile
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
